论文部分内容阅读
目的探讨乳腺癌组织中富含半胱氨酸的酸性分泌蛋白(SPARC)的表达水平及其与乳腺癌患者的临床病理特征的关系。方法选择92例诊疗、随访资料完整的乳腺癌患者作为病例组,选取30例健康妇女乳腺组织标本作为健康组,采用免疫组化法检测两组标本中SPARC表达水平的差异;统计分析病例组SPARC表达水平与临床病理特征及远期预后的关系。结果病例组的乳腺组织中SPARC表达(+)、(++)、(+++)率分别为15.22%、39.13%、23.91%,均高于健康组,健康组的(-)表达率高于病例组,病例组的SPARC表达阳性率显著高于健康组(P<0.05)。乳腺癌患者的乳腺肿瘤组织中SPARC表达阳性率与患者的年龄、是否绝经、TNM分期、淋巴结转移、病灶大小、组织学分化程度、孕激素受体表达情况均不具有相关性(P>0.05);SPARC在雌激素受体阴性的患者中表达阳性率为90.20%,显著高于雌激素受体阳性表达患者(63.41%),差异有统计学意义(P<0.05)。SPARC表达阳性与阴性的乳腺癌患者中位生存时间不具有统计学差异(χ~2=0.315,P=0.719);对未绝经乳腺癌患者根据SPARC表达分为阳性组与阴性组,采用生存分析法发现SPARC阴性表达的未绝经期患者中位生存时间显著长于SPARC阳性表达的患者(χ~2=3.892,P=0.031)。结论乳腺癌患者的SPARC阳性表达率显著高于正常人群,SPARC表达情况与雌激素受体具有一定的相关性,二者与患者的远期预后有关。
Objective To investigate the expression of cysteine-rich acidic secreted protein (SPARC) in breast cancer and its relationship with the clinicopathological features of patients with breast cancer. Methods Ninety-two patients with breast cancer who were diagnosed and followed up were selected as the case group. Thirty healthy women were selected as the healthy group, and the SPARC expression level was detected by immunohistochemistry. SPARC Relationship between expression level and clinicopathological features and long - term prognosis. Results The rates of (+), (++) and (+++) in breast tissues of cases were 15.22%, 39.13% and 23.91%, respectively, which were higher than those in healthy group In case group, the positive rate of SPARC expression in case group was significantly higher than that in healthy group (P <0.05). The positive rate of SPARC expression in breast cancer tissues was not correlated with age, whether menopause, TNM stage, lymph node metastasis, size of tumor, histological differentiation, progesterone receptor expression (P> 0.05) The positive expression rate of SPARC in estrogen receptor-negative patients was 90.20%, which was significantly higher than that in estrogen receptor positive patients (63.41%) (P <0.05). There was no significant difference in the median survival time between SPARC positive and negative breast cancer patients (χ ~ 2 = 0.315, P = 0.719). According to SPARC expression in patients with non-menopausal breast cancer, the median survival time was divided into two groups according to survival analysis The median survival time in patients with non-menopausal SPARC negative expression was significantly longer than that in patients with positive SPARC expression (χ ~ 2 = 3.892, P = 0.031). Conclusion The positive rate of SPARC in breast cancer patients is significantly higher than that in normal people. The expression of SPARC is related to estrogen receptor, both of which are related to the long-term prognosis of patients.